Department of Paediatric and Adolescent Surgery, Medical University of Graz, 8036 Graz, Austria.
Department of Paediatric Surgery, Clinical Center of Klagenfurt, 9020 Klagenfurt, Austria.
Nutrients. 2023 Aug 20;15(16):3655. doi: 10.3390/nu15163655.
Cancer therapy is often associated with severe side effects such as drug induced weight loss, also known as chemotherapy-induced cachexia. The aim of this study was to investigate the effects of a multispecies probiotic (OMNi-BiOTiC 10 AAD) in a chemotherapy mouse model. A total of 24 male BALB/c mice were gavage-fed with the probiotic formulation or water, once a day for 3 weeks. In the third week, the mice received intraperitoneal cyclophosphamide. At euthanasia, the organs were dissected, and serum was sampled for cytokine analysis. Tight junction components, myosin light chain kinase, mucins, and apoptosis markers were detected in the ileum and colon using histological analyses and qRT-PCR. Lipolysis was analyzed by enzymatic activity assay, Western blotting analyses, and qRT-PCR in WAT. The fecal microbiome was measured with 16S-rRNA gene sequencing from stool samples, and fecal volatile organic compounds analysis was performed using gas chromatography/mass spectrometry. The probiotic-fed mice exhibited significantly less body weight loss and adipose tissue wasting associated with a reduced CGI58 mediated lipolysis. They showed significantly fewer pro-inflammatory cytokines and lower gut permeability compared to animals fed without the probiotic. The colons of the probiotic-fed animals showed lower inflammation scores and less goblet cell loss. qRT-PCR revealed no differences in regards to tight junction components, mucins, or apoptosis markers. No differences in microbiome alpha diversity, but differences in beta diversity, were observed between the treatment groups. Taxonomic analysis showed that the probiotic group had a lower relative abundance of and and a higher abundance of . VOC analysis yielded no significant differences. The results of this study indicate that oral administration of the multispecies probiotic OMNi-BiOTiC 10 AAD could mitigate cyclophosphamide-induced chemotherapy side effects.
癌症治疗常伴有严重的副作用，如药物诱导的体重减轻，也称为化疗引起的恶病质。本研究旨在研究多菌种益生菌（OMNi-BiOTiC 10 AAD）在化疗小鼠模型中的作用。共 24 只雄性 BALB/c 小鼠经灌胃给予益生菌制剂或水，每天一次，连续 3 周。在第 3 周，小鼠接受腹腔注射环磷酰胺。安乐死后，解剖器官，取样血清进行细胞因子分析。用组织学分析和 qRT-PCR 检测回肠和结肠中的紧密连接成分、肌球蛋白轻链激酶、粘蛋白和凋亡标志物。通过酶活性测定、Western blot 分析和 qRT-PCR 分析 WAT 中的脂肪分解。通过粪便样本的 16S-rRNA 基因测序测量粪便微生物组，并用气相色谱/质谱法进行粪便挥发性有机化合物分析。与未给予益生菌的动物相比，给予益生菌的小鼠体重减轻和脂肪组织消耗明显减少，CGI58 介导的脂肪分解减少。它们表现出明显较少的促炎细胞因子和较低的肠道通透性。益生菌喂养动物的结肠炎症评分较低，杯状细胞丢失较少。qRT-PCR 显示紧密连接成分、粘蛋白或凋亡标志物无差异。治疗组之间观察到微生物组 α 多样性无差异，但 β 多样性有差异。分类分析显示，益生菌组的 和 相对丰度较低，而 的丰度较高。VOC 分析未产生显著差异。本研究结果表明，口服多菌种益生菌 OMNi-BiOTiC 10 AAD 可减轻环磷酰胺引起的化疗副作用。
